Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Viatris Inc (VTRS) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives

2026-02-26
Viatris Inc (VTRS) reports a 2% revenue increase for 2025, outlines cost-saving strategies, and anticipates new product launches to drive future growth.

Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript

2026-02-26
Viatris Inc. (VTRS) Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsWilliam Szablewski - Head of Investor Relations & Capital...

Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up

2026-02-26
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.

Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

2026-02-26
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates

2026-02-26
Viatris (VTRS) delivered earnings and revenue surprises of +9.62% and +5.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Wondering what's happening in today's S&P500 pre-market session?

2026-02-26
Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Viatris Inc (NASDAQ:VTRS) Beats Q4 2025 Estimates and Completes Strategic Review

2026-02-26
Viatris beats Q4 2025 earnings and revenue estimates, completes strategic review, and reaffirms dividend for 2026.

Viatris (NASDAQ:VTRS) Posts Better-Than-Expected Sales In Q4 CY2025

2026-02-26
Medication company Viatris (NASDAQ:VTRS) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 5% year on year to $3.7 billion. The company’s full-year revenue guidance of $14.7 billion at the midpoint came in 2.3% above analysts’ estimates. Its non-GAAP profit of $0.57 per share was 7.4% above analysts’ consensus estimates.

Viatris: Q4 Earnings Snapshot

2026-02-26
The Canonsburg, Pennsylvania-based company said it had a loss of 30 cents per share. Earnings, adjusted for one-time gains and costs, came to 57 cents per share. The results exceeded Wall Street expectations.

Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

2026-02-26
Viatris Inc. (Nasdaq: VTRS) today announced robust financial results for the fourth quarter and full year 2025. The Company also announced it has completed its enterprise-wide strategic review and expects to deliver meaningful net cost savings while enabling reinvestment in areas that enhance the growth profile and long-term competitiveness of the Company.